Observational study of effects of HIV Acquisition and Antiretroviral Treatment on Biomarkers of Systemic Immune Activation

Objective: Assess whether biomarkers of systemic inflammation are associated with HIV acquisition or with the timing of ART initiation (“immediate”, at diagnosis, versus “deferred”, at 24 weeks post-diagnosis) in men-who-have-sex-with-men (MSM) and transgender women. Design: A retrospective study comparing inflammatory biomarkers in participants’ specimens collected before and after ≥2 years of effective ART. Methods: Inflammatory biomarkers were measured in four longitudinally collected plasma specimens, including two plasma specimens collected from each participant before and two after HIV acquisition and confirmed ART-suppression. Biomarkers were quantified by enzyme-linked immuno-assay or Meso Scale Discovery. Statistical measures compared intra-participant and between-group changes in biomarkers. Results: Across 50 participants, the levels of C-reactive protein (CRP), monocyte chemo-attractant protein-1, tumor necrosis factor-α and interferon gamma-induced protein-10 significantly increased while leptin and lipopolysaccharide binding protein (LBP) significantly decreased following HIV infection. Randomization to deferred-ART initiation was associated with greater increases in CRP and no decreases in LBP. Multiple biomarkers varied significantly within participants’ two pre-infection or two post-ART-suppression specimens. Conclusions: Acquisition of HIV appeared to induce systemic inflammation, with elevation of biomarkers previously associated with infections and cardiovascular disease. Initiation of ART during the early weeks of infection tempered the increase in pro-inflammatory biomarkers compared to those who delayed ART for ~24 weeks after HIV diagnosis, perhaps because immediate-ART limited the size of the HIV reservoir or limited immune dysregulation. Some but not all biomarkers appeared sufficiently stable to assess intraparticipant changes over time. Given that pro-inflammatory biomarkers predict multiple co-morbidities, our findings suggest that immediate-ART initiation may improve health outcomes.

HIV reservoir or limited immune dysregulation. Some but not all biomarkers appeared sufficiently stable 48 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 8, 2023. ; https://doi.org/10.1101/2023.07.07.23292352 doi: medRxiv preprint 3 to assess intraparticipant changes over time. Given that pro-inflammatory biomarkers predict multiple co-49 morbidities, our findings suggest that immediate-ART initiation may improve health outcomes.

50
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

52
The progression of HIV disease to AIDS has been mitigated by antiretroviral treatment (ART) (1, 2, 3).

66
because ART initiated during primary infection limits the size of the HIV reservoir, we hypothesized that 67 PWH initiating ART at diagnosis during acute or early primary infection ("immediate" ART) would show 68 less immune activation compared to those who "deferred" ART for ~24 weeks.

71
Banked specimens from a prospective study of incident HIV infection among seronegative men-who-72 have-sex-with-men (MSM) and transgender women in Lima, Peru (Sabes Study) (16) were utilized to 73 evaluate immune biomarkers. Participants were enrolled into the Sabes Study between 7/16/2013 and 74 7/31/2015 followed through 9/10/2019 (date of last 4 th timepoint sample). All participants provided 75 written informed consent including consent for future use of specimens; personal identifiers were retained 76 at the study site in Lima (JRL) for participant tracking and were not available to other co-authors.

77
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 8, 2023.    CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 8, 2023. ; https://doi.org/10.1101/2023.07.07.23292352 doi: medRxiv preprint 6 two pre-infection or two post-suppression time-points, a two-sided, one-sample t-test was used to 104 separately compare values within each pair of pre-infection and post-suppression specimens. Biomarker 105 levels were also compared to physiologic "normal" ranges determined by assay manufacturers or clinical 106 studies (leptin, CRP, IFN-α2a) (25, 26). Because a prior study associated elevated plasma sCD14 levels 107 with efavirenz-based-ART(8), we further analyzed values across Visit-3 and -4 in participants switching 108 from efavirenz-to non-efavirenz-based regimens.

110
To identify biomarkers that differed following HIV infection despite more than six months of ART-   128 randomized to deferred-ART. Five participants randomized to deferred-ART initiated ART prior to 24-129 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 8, 2023. ; https://doi.org/10.1101/2023.07.07.23292352 doi: medRxiv preprint weeks post-HIV-diagnosis due to low CD4 cell counts or other ART-qualifying events and two of these 130 initiated ART in the immediate-ART timeframe and are included in the immediate-ART group for the 131 "as-treated" analysis; three initiated ART between the immediate-and the deferred-ART timeframes and 132 were excluded from the as-treated analysis, which is reported here. The mean interval from EDDI to ART 133 initiation for immediate-ART (N=21) and deferred-ART (N=26) groups were 39 (range:16-63) and 210 134 days (range:182-238), respectively (   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 8, 2023.

223
Our comparison of biomarker levels between those who initiated immediate-versus deferred-ART 224 initiation found that those treated immediately had significantly less elevation of their CRP and LBP 225 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 8, 2023. ; https://doi.org/10.1101/2023.07.07.23292352 doi: medRxiv preprint values. Earlier initiation of ART limits the size of the persistent viral reservoir (35), which should limit 226 production of viral nucleic acids and proteins that others have found associated with progression of 227 carotid artery intima thickness (13) or atherosclerotic plaque (14). The greater decrease in plasma IFN-228 α2a observed among those deferring ART (Figure 2) may be attributable to consistently high pre-229 infection values in this group. Notably, during ART all participants had IFN-α2a values in the normal 230 range of the assay (Figure 1).

232
While efavirenz in prior studies was associated with elevated sCD14 and kynurenine-tryptophan ratio (8, 233 36), we did not observe a significant change in sCD14 in participants who switched from efavirenz-based 234 ART to a "non-efavirenz" elvitegravir-based regimen. It is not known whether elvitegravir (or cobicistat, 235 contained in the co-formulated product to reduce hepatic clearance of elvitegravir) is associated with 236 inflammation, but it is notable that sCD14 levels were in the normal range for all specimens tested in the 237 study.

239
The primary limitations of this study are the relatively small size of the cohort examined, a relatively 240 short follow-up of the ART-suppressed participants for this life-long infection and the assessment of 241 biomarkers from relatively few timepoints. In addition, the relative youth of our study participants and the 242 short duration of their HIV infections limited our ability to observe non-AIDS adverse events, and we 243 were unable to conduct long term follow-up to observe and correlate our findings with clinical events.

244
Additionally, when evaluating the potential impact of efavirenz, we did not test some biomarkers found to 245 be abnormal in other studies, e.g., kynurenine/tryptophan ratio (8, 36). The primary strength of this study 246 comes from the comparison of two samples from before and two after documented incident HIV 247 infection. The two specimens prior and two after infection reduces variability due to extraneous events.

248
The study of individuals with incident infection diminishes the biases due to pre-existing conditions and 249 confounding behavioral practices, although, we acknowledge that behaviors may change following HIV 250 diagnosis (37).

251
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 8, 2023. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

317
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 8, 2023.

355
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 8, 2023. ; https://doi.org/10.1101/2023.07.07.23292352 doi: medRxiv preprint